ERBB2 and neoplasm: Clinically, combination treatment with endocrine therapy and HER2 inhibitors in patients with ER-positive breast cancer and HER2 activating mutations led to improved progression-free survival and duration of response when compared to endocrine therapy alone, thus showing benefit in combination approaches based on tumor characteristics [71].